Botanix Pharmaceuticals Ltd BXPHF

Morningstar Rating
$0.01 −0.00 (24.04%)
View Full Chart

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

BXPHF is trading at a LOCK|NLN#L premium.
Price
$0.01
Fair Value
LOCK|w$N%$$
Uncertainty
LOCK|%X
1-Star Price
LOCK|!Z!SGt
5-Star Price
LOCK|qSx#@P
Economic Moat
LOCK|Sb
Capital Allocation
—

Trading Information

Previous Close Price
$0.01
Day Range
$0.01–0.01
52-Week Range
$0.01–0.11
Bid/Ask
$0.00 / $0.02
Shares Outstanding
2.76B
Market Cap
$21.49M
Volume/Avg
117,700 / 100,401

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
0.75
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Dividend Payment Schedule
—
Total Yield
—

Company Profile

Botanix Pharmaceuticals Ltd is a pharmaceutical company. It launched Sofdra (sofpironium) topical gel, 12.45%, a prescription anticholinergic medicine used topically to treat excessive underarm sweating (primary axillary hyperhidrosis) in adults and children 9 years of age and older. Its mechanism of action targets the M3 receptor in the sweat gland, blocking acetylcholine to reduce sweat at its source. Its segments include Australia and United States which generates all of the revenue.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
1

Valuation

Metric
BXPHF
Price/Earnings (Normalized)
—
Price/Book Value
0.49
Price/Sales
0.75
Price/Cash Flow
—
Price/Earnings
No chart available

Financial Strength

Metric
BXPHF
Quick Ratio
1.40
Current Ratio
2.59
Interest Coverage
−23.98
Quick Ratio
BXPHF

Profitability

Metric
BXPHF
Return on Assets (Normalized)
−54.80%
Return on Equity (Normalized)
−91.96%
Return on Invested Capital (Normalized)
−61.96%
Return on Assets
BXPHF

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
LOCK|^t#SpnLOCK|#<##$133B
Regeneron Pharmaceuticals Inc
REGN
LOCK|!r>cLQLOCK|Ndx^$83B
Moderna Inc
MRNA
LOCK|%t>P@nLOCK|>zM$80B
argenx SE ADR
ARGX
LOCK|XN&&<HLOCK|@fb$55B
BeOne Medicines Ltd ADR
ONC
LOCK|M!??>yLOCK|tc$45B
Alnylam Pharmaceuticals Inc
ALNY
LOCK|<lL&^$?LOCK|V$&P$30B
Royalty Pharma PLC Class A
RPRX
LOCK|^#TzS>@RLOCK|CdlZd$28B
Incyte Corp
INCY
LOCK|<!WK#YwLOCK|?R&$23B
BioNTech SE ADR
BNTX
LOCK|X<zGD^LOCK|h$w$22B
Jazz Pharmaceuticals PLC
JAZZ
LOCK|?QFm#p$LOCK|VC$14B

Sponsor Center